KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Bristol Myers Squibb (BMY) over the last 17 years, with Q4 2025 value amounting to $5.0 billion.

  • Bristol Myers Squibb's Other Non-Current Liabilities rose 1284.4% to $5.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $5.0 billion, marking a year-over-year increase of 1284.4%. This contributed to the annual value of $5.0 billion for FY2025, which is 1284.4% up from last year.
  • According to the latest figures from Q4 2025, Bristol Myers Squibb's Other Non-Current Liabilities is $5.0 billion, which was up 1284.4% from $5.5 billion recorded in Q3 2025.
  • Bristol Myers Squibb's 5-year Other Non-Current Liabilities high stood at $7.7 billion for Q1 2021, and its period low was $4.5 billion during Q4 2024.
  • Over the past 5 years, Bristol Myers Squibb's median Other Non-Current Liabilities value was $6.5 billion (recorded in 2022), while the average stood at $6.2 billion.
  • Over the last 5 years, Bristol Myers Squibb's Other Non-Current Liabilities had its largest YoY gain of 1546.11% in 2025, and its largest YoY loss of 3349.67% in 2025.
  • Bristol Myers Squibb's Other Non-Current Liabilities (Quarter) stood at $7.3 billion in 2021, then decreased by 10.14% to $6.6 billion in 2022, then dropped by 2.56% to $6.4 billion in 2023, then tumbled by 30.4% to $4.5 billion in 2024, then rose by 12.84% to $5.0 billion in 2025.
  • Its Other Non-Current Liabilities stands at $5.0 billion for Q4 2025, versus $5.5 billion for Q3 2025 and $4.9 billion for Q2 2025.